Coolerr Bags Information
Promethera Biosciences SA, a global innovator in cell-based medicines and liver diseases, announced that clinical data from the ongoing phase 2a study of its lead product candidate HepaStem ® in patients with Acute-on-Chronic Liver Failure. Promethera Biosciences SA, a global innovator in cell-based medicines and liver diseases, announced that clinical data from the ongoing phase 2a study of its lead product candidate HepaStem ® in patients with Acute-on-Chronic Liver Failure. Promethera Biosciences SA, a global innovator in cell-based medicines and liver diseases, announced that clinical data from the ongoing phase 2a study of its lead product candidate HepaStem ® in patients with Acute-on-Chronic Liver Failure.
15.08.2019 / 12:00 > 4:00 PM 58 Greta Street
PROMETHERA BIOSCIENCES ANNOUNCES LATE-BREAKING DATA PRESENTATIONPromethera Biosciences SA, a global innovator in cell-based medicines and liver diseases, announced that clinical data from the ongoing phase 2a study of its lead product candidate HepaStem ® in patients with Acute-on-Chronic Liver Failure. Promethera Biosciences SA, a global innovator in cell-based medicines and liver diseases, announced that clinical data from the ongoing phase 2a study of its lead product candidate HepaStem ® in patients with Acute-on-Chronic Liver Failure. Promethera Biosciences SA, a global innovator in cell-based medicines and liver diseases, announced that clinical data from the ongoing phase 2a study of its lead product candidate HepaStem ® in patients with Acute-on-Chronic Liver Failure.
14.08.2019 / 7:00 > 12:00 PM ULiège - UMONS
UMONS, ULB, ULG INAUGURATE THE MASS SPECTROMETRY PLATFORM MS-QUANTAMasthercell announces today that it has signed a lease agreement for a 5.700 m2 facility located in Gosselies. The new facility will become a state-of-the-art manufacturing and production site designed for late-stage and commercially-approved cell. Masthercell announces today that it has signed a lease agreement for a 5.700 m2 facility located in Gosselies. The new facility will become a state-of-the-art manufacturing and production site designed for late-stage and commercially-approved cell. Masthercell announces today that it has signed a lease agreement for a 5.700 m2 facility located in Gosselies. The new facility will become a state-of-the-art manufacturing and production site designed for late-stage and commercially-approved cell.
01.08.2019 / 12:00 > 4:00 PM ULiège - UMONS
